Navigation Links
Personalizing prostate cancer screenings
Date:4/24/2013

CHICAGO --- With the help of genetics, prostate specific antigen (PSA) screenings may become more accurate and reduce the number of unnecessary prostate biopsies, according to a new study from Northwestern Medicine.

Personalized PSA testing using genetic variants could account for an 18 percent reduction in the number of men who likely would have undergone unnecessary biopsies, according to the study. It will be published in the May 2013 issue of The Journal of Urology.

The high survival rate of men with prostate cancer is largely a reflection of PSA testing, but support for the widespread use of the screening method has been the topic of recent debate because of its limited specificity.

"By utilizing a person's genetic makeup we can personalize care when he comes in for a PSA screening," said Brian Helfand, M.D., lead author of the study. "We may be able to prevent some men from having an unnecessary biopsy and prevent a delay in biopsy for men who may have an aggressive disease."

Helfand is an adjunct assistant professor of cell and molecular biology at Northwestern University Feinberg School of Medicine.

For 98 percent of the men, genetic adjustment of PSA levels did not change the outcome of their screening. But genetic correction was important for the 17 men who were reclassified as no longer meeting biopsy criteria and the three whose condition was up classified, and it was recommended they get a biopsy, based on their genetic adjustment.

"If our results are validated, genetic adjustments could potentially prevent 15 to 20 percent of prostate biopsies," said William J. Catalona, M.D., senior author of the study. "Since it has been estimated that more than 1 million biopsies are performed in the United States annually, this could translate into 150,000 to 200,000 potentially unnecessary biopsies every year."

In addition to cost savings, fewer biopsies mean fewer adverse outcomes, such as infection, sepsis and hospitalization, he said.

Catalona is a professor of urology at Feinberg, director of the clinical prostate cancer program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and an urologist at Northwestern Memorial Hospital.

Variants in genes, like those that help determine your height, are responsible for higher or lower levels of PSA expression. Recent studies have identified genetic variants associated with increased serum PSA concentrations, raising the possibility that a man's genetic make-up could interfere with an accurate PSA reading.

In this study, four variants previously associated with PSA levels were determined in 964 Caucasian volunteers without prostate cancer. Genetic correction of their PSA was performed by dividing each man's PSA value by his combined genetic risk. Analyses were used to compare the percentage of men who would meet commonly used biopsy thresholds (2.5 ng/ml or greater, or 4.0 ng/ml or greater) before and after genetic correction.

Assuming that a diagnostic laboratory has the available equipment, supplies and trained personnel, it would cost 60 cents per person to add genetic personalization to a PSA test.

The researchers are now investigating personalized PSA testing in black men and have plans to investigate genetic variants which impact PSA levels in other races as well.


'/>"/>

Contact: Erin White
ewhite@northwestern.edu
847-491-4888
Northwestern University
Source:Eurekalert

Related medicine news :

1. Personalizing prostate specific antigen testing may improve specificity, reduce biopsies
2. Personalizing medicine: New American Chemical Society Prized Science video
3. Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective
4. Obesity Linked to Prostate Cancer, Study Finds
5. Obese men at high risk for prostate cancer even after benign biopsy
6. Laser optics plus ultrasound imaging holds promise as a noninvasive test for prostate cancer
7. Gene-expression signature may signify risk for recurrence, metastasis in prostate cancer
8. New Procedure May Shrink Enlarged Prostate Without Surgery
9. Can Selenium Lower Risk of Advanced Prostate Cancer?
10. Counting copy numbers characterises prostate cancer
11. Prostate cancer treatment study changing the way doctors practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... As health professionals ... known as “patient engagement.” The patient is doing more than filling out a survey; ... , “There is an increasing emphasis in health care and research on the importance ...
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform ... leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led ...
Breaking Medicine Technology: